ATX-01 (ArthemiR trial)
Myotonic Dystrophy Type 1 (DM1)
Phase 1/2Active
Key Facts
About ARTHEx Biotech
ARTHEx Biotech is a private, clinical-stage biotech developing first-in-class anti-microRNA (anti-miR) therapies. The company's core technology involves oligonucleotides conjugated to fatty acids for improved tissue delivery, initially targeting the root cause of myotonic dystrophy type 1 (DM1). With its lead candidate, ATX-01, now in clinical trials (the ArthemiR trial), ARTHEx is positioned in the competitive RNA therapeutics space with a differentiated mechanism aimed at a severe, orphan genetic disease. The company is backed by a syndicate of European and US venture capital firms.
View full company profileTherapeutic Areas
Other Myotonic Dystrophy Type 1 (DM1) Drugs
| Drug | Company | Phase |
|---|---|---|
| AOC 1001 | Avidity Biosciences | Phase 1/2 |
| DYNE-101 | Dyne Therapeutics | Phase 1/2 |
| SRP-6004 | Sarepta Therapeutics | Phase 1/2 |
| Undisclosed | Design Therapeutics | Preclinical |
| PGN-EDODM1 | PepGen | Phase 2 |